FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

9 letters match. Newest first.

  1. Platinum Biologics LLC

    FDA says Platinum Biologics sells unapproved umbilical cord and exosome biologics without required licenses or approvals.

    High risk
  2. Chara Biologics, Inc.

    FDA warns Chara Biologics over unapproved, unlicensed CharaExo, CharaCore, CharaOmni.

    High risk
  3. Evolutionary Biologics Inc.

    FDA warned Evolutionary Biologics that its exosome and umbilical-cord products are unapproved new drugs and unlicensed biologics sold with disease-treatment claims.

    High risk
  4. Neobiosis, LLC

    FDA warns Neobiosis over unapproved amniotic fluid and umbilical cord products and serious manufacturing quality failures.

    High risk
  5. Kimera Labs, Inc.

    FDA warns Kimera Labs over unapproved exosome and amniotic fluid products and serious sterile manufacturing failures.

    High risk
  6. Abbott Laboratories

    FDA warns Abbott that Similac Probiotic Tri-Blend for preterm infants is an unapproved drug and adulterated supplement.

    High risk
  7. Invitrx Therapeutics, Inc.

    Invitrx Therapeutics made unapproved umbilical cord and exosome products and had serious manufacturing deviations.

    High risk
  8. BioLab Sciences, Inc.

    FDA warned BioLab Sciences that its injected amniotic fluid and skin products were unapproved biologics with serious manufacturing violations.

    High risk
  9. Utah Cord Bank LLC dba Utah Cell Bank

    Utah Cell Bank made unapproved injectable stem cell products and fell short on sterility and manufacturing controls, FDA found.

    High risk